Analyst Upgrades

• Morgan Joseph upgraded Cree (CREE) to buy from hold ahead of Tuesday's Q3 report. The firm, which has a $100 price target on the stock, expects LED demand to drive revenue growth as both China and the U.S. are increasingly strong.
• Janney Montgomery upgraded Salesforce.com (CRM) to buy from neutral on expectations the company will benefit from the migration of software to SaaS deployments. The firm upped its target price for shares to $94 from $67.
• Barrington upgraded Henry Schein (HSIC) to outperform from market perform, citing an attractive valuation, increased confidence in the outcome of the Butler-Schein Animal Health integration and improving momentum in dental equipment. The firm has a $74 price target for shares.
• Advance Auto Parts (AAP) was upgraded to buy from hold at BB&T.
• Red Hat (RHT) was upgraded to outperform from perform at Oppenheimer.
• UBS (UBS) was upgraded to overweight from neutral at HSBC.

MOST NOTEWORTHY: First Solar, JA Solar, Alcatel-Lucent, Nokia and Ericsson were today's noteworthy initiations:

• First Solar (NASDAQ: FSLR) and JA Solar Holdings (NASDAQ: JASO) were initiated with Buy ratings and targets of $160 and $61 at Collins Stewart. Collins Stewart sees room for margin expansion and is positive on First Solar after channel checks; the firm expects JA Solar to expand capacity given its long-term supply agreements with four wafer suppliers.
  
• Merrill Lynch started shares of Alcatel-Lucent (NYSE: ALU) with a Sell rating, citing a lack of revenue growth prospects.
  
• The firm also started shares of Nokia Corporation (NYSE: NOK) with a Buy rating, as they believe the company's share gains and margin expansion will continue.
  
• Merrill also resumed coverage of Ericsson (NASDAQ: ERIC) with a Neutral rating, expecting high single digit earnings and share growth, but not enough for a Buy rating.

OTHER INITIATIONS:

• Goldman initiated the trucking and railroad sectors with Neutral ratings.
  
• Wachovia initiated Isis Pharmaceuticals (NASDAQ: ISIS), BioMarin and Molecular Insight (NASDAQ: MIPI) with Outperform ratings and Bioenvision (NASDAQ: BIVN), Dendreon Corporation (NASDAQ: DNDN), Arena Pharmaceuticals (NASDAQ: ARNA) and Neurocrine Biosciences (NASDAQ: NBIX) with Market Perform ratings.

MOST NOTEWORTHY: Time Warner Cable (TWC) and Molecular Insight Pharmaceuticals (MIPI) were today's more notable initiations:

• Time Warner Cable (NYSE: TWC) was initiated at Bernstein with an Outperform rating and $46 target, citing a compelling diversification alternative for cable/CMCS investors. Goldman started Time Warner Cable with a Neutral rating and $44 target.

• Molecular Insight Pharmaceuticals Inc (NASDAQ: MIPI) was initiated at RBC with an Outperform rating and $18 target. RBC said Molecular Insight is a leader in developing and commercializing superior radiopharmaceuticals for the treatment and management of life-threatening diseases. Jefferies initiated shares of Molecular Insight with a Buy rating and $20 target, saying Zemiva has blockbuster potential.

OTHER INITIATIONS:

• UBS started Amedisys, Inc (NASDAQ: AMED) with aBuy rating and $39 target.

• Goldman Sachs initiated TransCanada (NYSE: TRP) with a Buy rating.

• Credit Suisse initiated Tim Hortons Inc (NYSE: THI) with an Outperform rating.

• Pacific Growth initiated Ormat Technologies, Inc (NYSE: ORA) with a Buy rating.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).